- ￥156 - 3746
- MedChemExpress(MCE)
- 美国
- HY-18204
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 英文名：
CGP 48933
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
137862-53-4
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/25 mg/50 mg/100 mg/200 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥299.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥156.0 |
| 规格： | 5 mg | 产品价格： | ￥312.0 |
| 规格： | 10 mg | 产品价格： | ￥500.0 |
| 规格： | 25 mg | 产品价格： | ￥1000.0 |
| 规格： | 50 mg | 产品价格： | ￥1600.0 |
| 规格： | 100 mg | 产品价格： | ￥2400.0 |
| 规格： | 200 mg | 产品价格： | ￥3746.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Valsartan
CAS No. : 137862-53-4
MCE 国际站：Valsartan
产品活性：Valsarta (CGP 48933) 是血管紧张素 II (angiotensin II) 受体拮抗剂，有潜力用于高血压和心力衰竭的研究。
研究领域：GPCR/G Protein
作用靶点：Angiotensin Receptor
In Vitro: Valsartan (CGP 48933) is a synthetic non-peptide angiotensin II type 1 receptor antagonist that dilates blood vessels and reduces blood pressure by blocking the action of angiotensin. Valsartan significantly decreases the expression of AT1R in ageing aorta endothelial cells.
The pretreatment of valsartan results in an inhibition of TLR2 signaling and proinflammatory cytokines. The expression of AGTR1 is up-regulated after alcohol exposure, and is blocked by valsartan pretreatment.
In Vivo: Valsartan (CGP 48933) significantly attenuates the expression of TGF-β/Smad, Hif-1α and fibrosis-related protein in rats after MI. Heart function, infarcted size, wall thickness as well as myocardial vascularization of ischaemic hearts are also significantly improved by valsartan compared with saline and hydralazine.
Valsartan partially reverses the effects of high-salt diet on hypertension, cardiac injuries such as fibrosis and inflammatory cell infiltration, and inhibition of aquaporin 1 and angiogenic factors; valsartan alone does not exert such effects.
Valsartan is an effective antidepressant/antianxiety reagent and can promote the hippocampal neurogenesis and expression of BDNF. Chronic administration of valsartan (5-40 mg/kg/d, p.o.) increases the time spent in the center of the field in OFT and the latency to eat in NSF, reduces the immobility time in both TST and FST, and increases the sucrose preference in SPT.
相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | FDA-Approved Drug Library | Antiviral Compound Library | Peptidomimetic Library | Drug Repurposing Compound Library | Anti-diabetic Compound Library | Anti-Cardiovascular Disease Compound Library | Endocrinology Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | Neurotransmitter Receptor Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Angiogenesis-Related Compound Library | Rare Diseases Drug Library | Children’s Drug Library | EMA-Approved Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Non-steroidal Anti-Inflammatory Compound Library | Off-patent Drug Library | Antihypertensive Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Angiotensin II human | Losartan | Telmisartan | Tranilast | A 779 | Buloxibutid | AVE 0991 | Sacubitril/Valsartan | Candesartan | Irbesartan | YS-49 | Nitrosoglutathione | Olmesartan | Olodanrigan | PD 123319 ditrifluoroacetate | CGP-42112 | Talfirastide acetate | Alamandine | Azilsartan medoxomil | Angiotensin II 5-valine | Sparsentan | TRV-120027 TFA | Angiotensin III, human, mouse | Angiotensin II (3-8), human TFA
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
